8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Published . Updated .
Key takeaways
- 8-K - Vistagen Therapeutics filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
- Exposed: VTGN
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Vistagen Therapeutics filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
Directly affected
- VTGN Vistagen Therapeutics-29.9% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Vistagen Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+14.3% 30d
Eli Lilly and is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+3.3% 30d
Johnson & Johnson is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+9.3% 30d
AbbVie is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.4% 30d
Merck is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+6.8% 30d
Abbott Laboratories is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| VTGN | +0.97% | +13.39% | base | after close | after close | after close | after close |
| XLV | -0.10% | +2.63% | base | after close | after close | after close | after close |
| LLY | +4.21% | +4.67% | base | after close | after close | after close | after close |
| JNJ | -2.08% | +0.00% | base | after close | after close | after close | after close |
| ABBV | -0.93% | +1.16% | base | after close | after close | after close | after close |
| MRK | +1.15% | +2.46% | base | after close | after close | after close | after close |
| ABT | +0.28% | +5.08% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-09 AccNo: 0001628280-26-071910 Size: 213 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Vistagen Therapeutics (VTGN)
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +1.16% | final price |
| ABBV | five days earlier | -0.93% | final price |
| ABT | three days earlier | +5.08% | final price |
| ABT | five days earlier | +0.28% | final price |
| JNJ | three days earlier | 0.00% | final price |
| JNJ | five days earlier | -2.08% | final price |
| LLY | three days earlier | +4.67% | final price |
| LLY | five days earlier | +4.21% | final price |
| MRK | three days earlier | +2.46% | final price |
| MRK | five days earlier | +1.15% | final price |
| Vistagen Therapeutics (VTGN) | three days earlier | +13.39% | final price |
| Vistagen Therapeutics (VTGN) | five days earlier | +0.97% | final price |
| XLV | three days earlier | +2.63% | final price |
| XLV | five days earlier | -0.10% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 66 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 40 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 45 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 62 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 56 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 66 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 46 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 82 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 38 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 52 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 53 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Vistagen Therapeutics (VTGN)
Companies mentioned with this story
- VTGN Vistagen Therapeutics
In “8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer),” Vistagen Therapeutics (VTGN) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> VTGN
How “8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)” reaches Vistagen Therapeutics (VTGN)
“8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)” (9 Nov 2026) reaches Vistagen Therapeutics (VTGN) through this story.
For Vistagen Therapeutics (VTGN), the reason on file says SEC 8-K filing -> direct issuer disclosure -> VTGN
Dates and price levels for Vistagen Therapeutics (VTGN)
VTGN traded between 0.17 and 0.24 across 20 sessions. The latest close on file is 0.17.
A simple score for Vistagen Therapeutics (VTGN)
14 out of 100
“8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.